Cargando…
Stroke Prevention: Managing Modifiable Risk Factors
Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504482/ https://www.ncbi.nlm.nih.gov/pubmed/23213626 http://dx.doi.org/10.1155/2012/391538 |
_version_ | 1782250638471593984 |
---|---|
author | Di Legge, Silvia Koch, Giacomo Diomedi, Marina Stanzione, Paolo Sallustio, Fabrizio |
author_facet | Di Legge, Silvia Koch, Giacomo Diomedi, Marina Stanzione, Paolo Sallustio, Fabrizio |
author_sort | Di Legge, Silvia |
collection | PubMed |
description | Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke. |
format | Online Article Text |
id | pubmed-3504482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-35044822012-12-04 Stroke Prevention: Managing Modifiable Risk Factors Di Legge, Silvia Koch, Giacomo Diomedi, Marina Stanzione, Paolo Sallustio, Fabrizio Stroke Res Treat Review Article Prevention plays a crucial role in counteracting morbidity and mortality related to ischemic stroke. It has been estimated that 50% of stroke are preventable through control of modifiable risk factors and lifestyle changes. Antihypertensive treatment is recommended for both prevention of recurrent stroke and other vascular events. The use of antiplatelets and statins has been shown to reduce the risk of recurrent stroke and other vascular events. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are indicated in stroke prevention because they also promote vascular health. Effective secondary-prevention strategies for selected patients include carotid revascularization for high-grade carotid stenosis and vitamin K antagonist treatment for atrial fibrillation. The results of recent clinical trials investigating new anticoagulants (factor Xa inhibitors and direct thrombin inhibitors) clearly indicate alternative strategies in stroke prevention for patients with atrial fibrillation. This paper describes the current landscape and developments in stroke prevention with special reference to medical treatment in secondary prevention of ischemic stroke. Hindawi Publishing Corporation 2012 2012-11-04 /pmc/articles/PMC3504482/ /pubmed/23213626 http://dx.doi.org/10.1155/2012/391538 Text en Copyright © 2012 Silvia Di Legge et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Di Legge, Silvia Koch, Giacomo Diomedi, Marina Stanzione, Paolo Sallustio, Fabrizio Stroke Prevention: Managing Modifiable Risk Factors |
title | Stroke Prevention: Managing Modifiable Risk Factors |
title_full | Stroke Prevention: Managing Modifiable Risk Factors |
title_fullStr | Stroke Prevention: Managing Modifiable Risk Factors |
title_full_unstemmed | Stroke Prevention: Managing Modifiable Risk Factors |
title_short | Stroke Prevention: Managing Modifiable Risk Factors |
title_sort | stroke prevention: managing modifiable risk factors |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3504482/ https://www.ncbi.nlm.nih.gov/pubmed/23213626 http://dx.doi.org/10.1155/2012/391538 |
work_keys_str_mv | AT dileggesilvia strokepreventionmanagingmodifiableriskfactors AT kochgiacomo strokepreventionmanagingmodifiableriskfactors AT diomedimarina strokepreventionmanagingmodifiableriskfactors AT stanzionepaolo strokepreventionmanagingmodifiableriskfactors AT sallustiofabrizio strokepreventionmanagingmodifiableriskfactors |